Tinder Swindler, Simon Leviev, Speaks Out After The Documentary

Simon Leviev, the infamous ‘Tinder Swindler,’ has broken his silence since the Netflix documentary aired. During an interview with Inside Edition, the Israeli-born con artist has denied any wrongdoing.

Simon, aka Shimon Hayut, was quoted as saying, “I’m not this monster. I was just a single guy that wanted to meet some girls on Tinder.”

Also read – Here’s What The ‘The Tinder Swindler’ Didn’t Tell You About Simon Leviev

He also claimed that he was a victim of a witch hunt after his dating exploits were exaggerated by the documentary. The 31-year-old conman has been accused of scamming women out of $10 million.

“They presented it as a documentary, but in truth, it’s a completely made-up movie. I’m the biggest gentleman in the world.” He said

Supporting his claims was Hayut’s 24-year-old, Ukraine-born Israeli model girlfriend Kate Konlin, who also briefly featured in the Netflix documentary. She said she did not believe the women who claimed to be scammed, and added that he has never borrowed money from her.

“My god, it is like, how someone can build such a fake story,” said Konlin.

On the claims of posing as a son of a billionaire diamond mogul, the twice-convicted fraudster said, “They weren’t conned and they weren’t threatened. No, I am not, and I never presented myself the son of a billionaire diamond mogul.”

Adding “I’m a legit businessman. I got into Bitcoin in 2011, it was nothing. I don’t need to say how much it is worth now.”

When asked if he feels sorry for what his victims have gone through he said “I feel bad for something that I didn’t do? No, I feel bad for whatever happened to myself. I want to clear my name. I want to say to the world, this is not true.”

“I am not a fraud and I’m not a fake. People don’t know me, so they cannot judge me,” Hayut added.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer thumbnail

Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer

Not intended for U.S. and UK Media Berlin, March 1, 2023 – The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa™ (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is
Read More
Chicago firm partners with CommonWell to tackle health disparities via data exchange thumbnail

Chicago firm partners with CommonWell to tackle health disparities via data exchange

CareAdvisors, a Chicago-based health technology firm, introduced what it's calling an "equity information exchange" this past week, aimed at enabling network partners to share medical and social data about vulnerable patients.   The EIX provides access to more than 150 million patient records nationwide via the Commonwell Health Alliance.   "With an EIX, patients and…
Read More
Surge in supply chain shortages disrupting hospital operations thumbnail

Surge in supply chain shortages disrupting hospital operations

Skip to main content MH Illustration/Getty images Scripps Health has about eight times more medical devices and supplies on backorder than the integrated nonprofit health system had in 2019. San Diego, California-based Scripps has been managing shortages in ligatures and oxygenators that stop bleeding, catheters used in heart surgery and urology and custom procedure trays
Read More
Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC thumbnail

Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC

Oncology/Hematology > Lung Cancer — But how well will the results from China translate to Western populations? by Mike Bassett, Staff Writer, MedPage Today February 16, 2024 Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

Total
0
Share